The Shkre­li rule? FDA is ex­plor­ing whether se­lect­ed reim­por­ta­tion could crip­ple the drug prof­i­teers

Mar­tin Shkre­li was hauled in front of law­mak­ers, jailed on fraud con­vic­tions and sub­ject­ed to every known form of le­gal pres­sure af­ter hik­ing the price of Dara­prim by more than 5000%. But none of it worked to force him to back off a per­fect­ly le­gal strat­e­gy to gouge pay­ers on a nar­row­ly con­trolled gener­ic drug — where the sky is the lim­it on the price.

So now the FDA is ex­plor­ing a new op­tion, which in­volves a tac­tic that the drug in­dus­try — and many oth­ers in the gov­ern­ment — have long ab­horred.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER